Lupin launches oral therapy for bacterial vaginosis in US market

Leading pharma company Lupin has launched Solosec, a single-dose oral therapy for bacterial vaginosis in the US market.

Solosec or secnidazole is a next-generation 5-nitroimidazole antimicrobial agent prescribed for the treatment of bacterial vaginosis (BV) in women. The 2g oral granule delivers a full course therapy in a single dose for the most common vaginal infection among women of childbearing age.

In October 2017, Lupin acquired Symbiomix Therapeutics and Solosec franchise for a cash consideration of US$ 150 million. Symbiomix offers innovative therapies for gynecologic infections.

Also, the company has informed that Nicholas Hart as been appointed by President of Specialty, US Business. He will be responsible for business growth strategy, P&L and organisation of Lupin's Specialty Brand in the US market.

Lupin is a leading generic pharmaceutical company engaged in cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID segment with global leadership in the anti-TB segment.

On Thursday, at 14:22 hours, the stock of Lupin was quoting Rs. 771.50 per share, 0.87 per cent.